GRIFOLS S A/S (NASDAQ:GRFS) Downgraded to “Buy” at BidaskClub

BidaskClub cut shares of GRIFOLS S A/S (NASDAQ:GRFS) from a strong-buy rating to a buy rating in a report released on Tuesday morning, BidAskClub reports.

A number of other brokerages have also weighed in on GRFS. JPMorgan Chase & Co. upgraded shares of GRIFOLS S A/S from a neutral rating to an overweight rating and boosted their price objective for the stock from $21.00 to $22.50 in a report on Thursday, June 27th. ValuEngine lowered shares of GRIFOLS S A/S from a hold rating to a sell rating in a report on Thursday, August 1st. Finally, Zacks Investment Research upgraded shares of GRIFOLS S A/S from a sell rating to a hold rating in a report on Thursday, August 15th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and a consensus price target of $20.75.

Shares of GRFS opened at $21.88 on Tuesday. The firm has a market cap of $15.16 billion, a price-to-earnings ratio of 18.70, a PEG ratio of 1.36 and a beta of 1.11. The company has a debt-to-equity ratio of 1.38, a quick ratio of 0.95 and a current ratio of 2.68. GRIFOLS S A/S has a fifty-two week low of $17.42 and a fifty-two week high of $23.03. The firm has a 50 day moving average price of $22.02 and a 200-day moving average price of $19.87.

Institutional investors and hedge funds have recently made changes to their positions in the company. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in GRIFOLS S A/S by 9.1% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 6,296 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 526 shares during the last quarter. Wetherby Asset Management Inc. raised its holdings in GRIFOLS S A/S by 5.5% during the 2nd quarter. Wetherby Asset Management Inc. now owns 16,189 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 849 shares during the last quarter. Advisors Asset Management Inc. raised its holdings in GRIFOLS S A/S by 40.8% during the 1st quarter. Advisors Asset Management Inc. now owns 5,108 shares of the biotechnology company’s stock valued at $103,000 after buying an additional 1,479 shares during the last quarter. Lenox Wealth Management Inc. raised its holdings in GRIFOLS S A/S by 0.7% during the 1st quarter. Lenox Wealth Management Inc. now owns 236,947 shares of the biotechnology company’s stock valued at $4,765,000 after buying an additional 1,652 shares during the last quarter. Finally, Bank of Montreal Can raised its holdings in GRIFOLS S A/S by 2.3% during the 1st quarter. Bank of Montreal Can now owns 89,850 shares of the biotechnology company’s stock valued at $1,807,000 after buying an additional 2,017 shares during the last quarter. Hedge funds and other institutional investors own 18.00% of the company’s stock.

GRIFOLS S A/S Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes a range of biological medicines on plasma derived proteins worldwide. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use; and sells and distributes end products.

See Also: The role of implied volatility with call option volume

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.